Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapy

Oncology Letters

Volumn 1, Issue 1, 2010, Pages 23-29

  Nam, Taek Keun ^a   Lee, Ji Shin ^a   Kim, Hyeong Rok ^a   Ahn, Sung Ja ^a   Song, Ju Young ^a   Yoon, Mee Sun ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

hMLH1; MDM2; p53; pRb; Preoperative chemoradiotherapy; Rectal neoplasms

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; FORMALDEHYDE; PARAFFIN; PROTEIN MDM2; PROTEIN MLH1; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PREOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PROGNOSIS; PROTEIN EXPRESSION; RECTUM BIOPSY; RECTUM CANCER; TISSUE CULTURE; TREATMENT OUTCOME;

EID: 77955755045     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000004     Document Type: Article

References (39)

1. Janjan NA, Khoo VS, Abbruzzese J, et al: Tumor down-staging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 44: 1027-1038, 1999.
2. Kim JS, Cho MJ, Song KS and Yoon WH: Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 54: 403-408, 2002.
3. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740, 2004.
4. Navarro M, Dotor E, Rivera F, et al: A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 66: 201-205, 2006.
5. Kim YH, Kim DY, Kim TH, et al: Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancer. Int J Radiat Oncol Biol Phys 62: 761-768, 2005.
6. Chang HJ, Jung KH, Kim DY, et al: Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol 36: 364-371, 2005.
7. Giralt J, De las Heras M, Cerezo L, et al: The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 74: 101-108, 2005.
8. Kim JS, Kim JM, Li S, et al: Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 66: 195-200, 2006.
9. Rau B, Sturm I, Lage H, et al: Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 21: 3391-3401, 2003.
10. Rodel F, Capalbo G, Rodel C and Weiss C: Caveolin-1 as a prognostic marker for local control after preoperative chemoradiation therapy in rectal cancer. Int J Radiat Oncol Biol Phys 73: 846-852, 2009.
11. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
12. Adell G, Sun XF, Stal O, Klintenberg C, Sjodahl R and Nordenskjold B: p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer. Radiother Oncol 51: 169-174, 1999.
13. Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin Rand Laurent-Puig P: Prognostic value of p53 mutations in rectal carcinoma. Int J Cancer 100: 131-135, 2002.
14. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
15. Cui X, Shirai Y, Wakai T, Yokoyama N, Hirano Sand Hatakeyama K: Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol 35: 1189-1195, 2004.
16. Ioachim E: Expression patterns of cyclins D1, Eand cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features. Int J Clin Pract 62: 1736-1743, 2008.
17. Fink D, Aebi S and Howell SB: The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4: 1-6, 1998.
18. Fishel R: The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. Cancer Res 61: 7369-7374, 2001.
19. Charara M, Edmonston TB, Burkholder S, et al: Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FUand CPT-11 chemotherapy and radiotherapy. Anticancer Res 24: 3161-3167, 2004.
20. Bertolini F, Bengala C, Losi L, et al: Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 68: 1455-1461, 2007.
21. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
22. Kondo I, Iida S, Takagi Y and Sugihara K: MDM2 mRNA expression in the p53 pathway may predict the potential of invasion and liver metastasis in colorectal cancer. Dis Colon Rectum 51: 1395-1402, 2008.
23. Forslund A, Zeng Z, Qin LX, et al: MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers. Mol Cancer Res 6: 205-211, 2008.
24. Kudrimoti M, Lee EY, Kang Y, Ahmed M and Mohiuddin M: Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers. J Ky Med Assoc 105: 18-22, 2007.
25. Tzouvala M, Lazaris AC, Papatheodoridis GV, et al: Potential role of apoptosis and apoptotic regulatory proteins in colorectal neoplasia: correlations with clinico-pathological parameters and survival. Dig Dis Sci 53: 451-460, 2008.
26. Xia F, Wang X, Wang YH, Tsang NM, Yandell DW, Kelsey KT and Liber HL: Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 55: 12-15, 1995.
27. Shimoji H, Miyazato H, Nakachi A, et al: Expression of p53, bcl-2 and bax as predictors of response to radiotherapy in esophageal cancer. Dis Esophagus 13: 185-190, 2000.
28. Lin LC, Lee HH, Hwang WS, et al: p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol 15: 211-216, 2006.
29. Terzi C, Canda AE, Sagol O, et al: Survivin, p53 and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Int J Colorectal Dis 23: 37-45, 2008.
30. Gosens MJ, Dresen RC, Rutten HJ, et al: Preoperative radiochemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumours. Ann Oncol 19: 2026-2032, 2008.
31. Guy M, Moorghen M, Bond JA, Collard TJ, Paraskeva C and Williams AC: Transcriptional down-regulation of the retinoblastoma protein is associated with differentiation and apoptosis in human colorectal epithelial cells. Br J Cancer 84: 520-528, 2001.
32. Ikeguchi M, Ueda T, Fukuda K, Yamaguchi K, Tsujitani S and Kaibara N: Expression of the murine double-minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemoradiotreatment. Am J Clin Oncol 25: 454-459, 2002.
33. Garcia del Muro X, Condom E, Vigues F, et al: p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 100: 1859-1867, 2004.
34. McKay JA, Douglas JJ, Ross VG, et al: Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol 196: 386-393, 2002.
35. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M and Wang JY: The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806-809, 1999.
36. Davis TW, Wilson-Van Patten C, Meyers M, et al: Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res 58: 767-778, 1998.
37. Nam TK, Lee JH, Cho SH, et al: Low hMLH1 expression prior to definitive chemoradiotherapy predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Lett 260: 109-117, 2008.
38. Geyer RK, Yu ZK and Maki CG: The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2: 569-573, 2000.
39. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR and Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698, 1995.